Survival Analysis in Advanced Non Small Cell Lung Cancer Treated with Platinum Based Chemotherapy in Combination with Paclitaxel, Gemcitabine and Etoposide

Association of MDR1 Gene (C3435T) Polymorphism and Gene Expression Profiling in Lung Cancer Patients Treated with Platinum-Based Chemotherapy

“…MDR1 polymorphism (rs1045642) C3435T in exon 26 may co-determine resistance to chemotherapy and provide useful information to individualize therapy. Chemotherapy drugs are most effective when given in combination (combination chemotherapy) rather than as mono-agents [15,16]. However, the dose depends on the individual's disease status (locally advanced or metastatic), age [even after considering the body surface area (BSA)], body mass index (BMI), BSA, low blood count, based on other treatments (radiotherapy or surgery), ECOG (Eastern Cooperative Oncology Group) performance status and any other life-threatening diseases.…”

Clinical Observation of Whole Brain Radiotherapy Concomitant with Targeted Therapy for Brain Metastasis in Non-small Cell Lung Cancer Patients with Chemotherapy Failure

“…NSCLC in progressive stage has great rate of developing brain metastasis and poor prognosis (Li et al, 2013;Liu et al, 2013;Natukula et al, 2013). Medium survival time (MST) without any treatment is only 1 month in NSCLC patients with brain metastasis, while it is 2~3 months in those being positively treated with dehydration and hormone, and 6 months after whole brain radiotherapy (Gianfranco et al, 2012).…”

Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer

“…Gefitinib, EGFR tyrosine kinase inhibitor and aniline quinazoline compounds with low molecular weight, can competitively bind to EGFR tyrosine kinase and block EGFR-mediated tumor cell signaling, thus inhibiting the proliferation and metastasis, and angiogenesis of tumor and promoting the apoptosis of tumor cells (Fukuoka et al, 2011;Lee et al, 2013). With the application of new chemotherapeutics such as navelbine, paclitaxel, ene paclitaxel and gefitinib in clinic in recent years, the chemotherapy regimens of combined with cisplatin can greatly enhance the survival rate of advanced NSCLC (Heinermann, et al, 2009;Mill, et al, 2011;Natukula et al, 2013;Di et al, 2014). At present, gemcitabine combined with cisplatin is one of the standard first-line regimens for advanced SNCLC, but with the most common adverse reactions of combined chemotherapy such as myelosuppression and part of late patients difficult to tolerate (Giorgio et al, 2008).…”